Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

GLP-1s may suppress the centers in the brain responsible for cravings—the same mechanism that could contribute to weight loss ...

GLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Salk Institute researchers have identified a key protein that may help users of GLP-1 drugs such as Ozempic and Wegovy ...

A recent study has revealed an increased risk of thyroid cancer diagnoses within the first year of starting GLP-1RA therapy.